Why we Partner


We are part of an industry that is lauded for producing innovative therapies that change patients’ lives. It is an industry that has fostered incredible scientific development, producing drugs to treat a range of conditions from heart failure and thrombosis to multiple cancer treatments.

We want to continue developing innovative treatments as efficiently as possible so we value collaboration with likeminded partners who share our quest to provide new options for patients. Here are some of the reasons why we partner:

Joerg Moeller
Strong partnerships have the power to spark innovation. We want to complement our comprehensive in-house expertise with the know-how of excellent partners from academia and industry.
Dr. Joerg Moeller
Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development

To bring new treatments to patients quicker than before

We will do whatever it takes to deliver solutions to patients. For us, innovation isn’t limited to the next major breakthrough therapy – we also celebrate the seemingly smaller successes because we know there are patients waiting for new ways in which they can live better. Partnering gives us the chance to establish scientific relationships across indications to foster scientific progress and benefits for patients. Our ultimate goal is always to provide more options for patients as fast and efficiently as possible.

Hong Wu
Our collaboration exemplifies how academic creativity and industrial drug development experiences can be perfectly combined.
Prof. Hong Wu
Dean of School of Life Sciences of Peking University

To extend our existing knowledge and expertise

We are proud of our in-house expertise and we have scores of people who work hard to find new solutions to some of healthcare’s most challenging problems. However, we cannot possibly claim to know everything. We welcome different forms of collaboration: from traditional licensing agreements or strategic alliances to public-private partnerships, consortia or open innovation models. By complementing our internal capabilities with the know-how of exceptional partners, we have access to a vast pool of expertise that we can tap into to improve research and development of new medicines.

To speed up innovation

We want to take advantage of the latest trends so we are flexible when it comes to how we foster medical innovation. New models of collaboration have emerged and are rapidly increasing in number. These new alliances are broad; they involve entire departments and even entire institutions. By finding new and creative approaches to build upon and harness such knowledge, we can speed up the time it takes to research and development innovative medicines.

To maintain connections to the global scientific community

We are geographically flexible - that means that we go where the science is. We have five Innovation Centers in some of the most vibrant cities across the world so we can maintain our local scientific networks and are looking for new collaborations all the time.

We do a lot of R&D in partnership and the way we do it is constantly evolving. The types of partnership we have today are different from those we had ten years ago. We must remain flexible in light of the changes in our industry so I’m fairly certain that in five to ten years, the way in which we partner will have changed again.
Chandra Ramanathan
Head of R&D Open Innovation Pharmaceuticals

Different ways of partnering

Why do we do it?

We don’t collaborate simply to enhance our geographic or commercial footprint, but to pool expertise and portfolios. Sharing know-how can accelerate the research and development process and ensure that we bring drugs to patients faster than before.



What are the results?

Bayer has dedicated departments that identify promising technologies and assets from other companies that have a strong potential for successful innovation. These late stage collaborations focus on compounds in Phase I studies and beyond.


One such example is our collaboration with Loxo Oncology to develop compounds to treat patients suffering from cancers that harbor a specific gene fusion called neurotrophic tyrosine receptor kinase (NTRK). Loxo Oncology has already submitted the first product from this collaboration to the U.S. Food and Drug Administration to apply for marketing authorization. We hope that this cooperation will soon provide hope for children and adults with difficult-to-treat cancers.


We also partner with companies at an earlier development stage. For example, since 2012, Bayer has been in collaboration with Evotec, an external innovation drug discovery and development company. The partnership began with the research and development of new treatment options for the neglected disease of endometriosis. Since 2016, we have also entered into a partnership to research and develop drugs for the treatment of kidney diseases.



We are proud to be the partner of choice for Bayer to develop a first in class treatment to fight endometriosis.

Dr. Werner Lanthaler, CEO of Evotec AG

Why do we do it?

The number of collaborations between industry and academia or consortia is increasing rapidly. Such alliances are broad and contribute to entire therapeutic areas, not only single compounds, and often last for years.


What are the results?

Bayer now has over 30 collaborations with academic institutions. One such example is our work together with the renowned Broad Institute of MIT and Harvard, one of the leading global research institutes in biomedicine. The partnership began in 2013 with a focus on finding new ways to tackle cancer. In 2015, we began a new collaboration focusing on heart and blood (cardiovascular) diseases which uses insights from human genetics to help create new therapies. Most recently, we opened a joint precision cardiology laboratory in June 2018 to further our combined research of new ways to treat patients with cardiovascular diseases such as heart failure.